Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturing in 2031 and $500 million of 4.900% senior notes maturing in 2034. The offering is expected to close on May 20, 2026, subject to customary closing conditions.

Gilead intends to use the net proceeds from this offering for general corporate purposes, which may include funding for acquisitions, investments, strategic transactions or other business opportunities.

Barclays Capital Inc., BofA Securities, Inc. and Citigroup Global Markets Inc. are acting as lead joint book-running managers in the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of Gilead's effective shelf registration statement on Form S-3 (File No. 333-273745), copies of which may be obtained from:

Barclays Capital Inc.

c/o Broadridge Financial Solutions,

1155 Long Island Avenue

Edgewood, NY 11717

(888) 603-5847

Email: barclaysprospectus@broadridge.com

BofA Securities, Inc.

NC1-022-02-25

201 North Tryon Street

Charlotte, NC 28255

(800) 294-1322

Email: dg.prospectus_requests@bofa.com

Citigroup Global Markets Inc.

c/o Broadridge Financial Solutions,

1155 Long Island Avenue

Edgewood, NY 11717

(800) 831-9146

Email: prospectus@citi.com

An electronic copy of the prospectus supplement and the accompanying base prospectus and other documents Gilead has filed with the U.S. Securities and Exchange Commission (the "SEC") may also be obtained at no charge at the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the current market demand for these types of securities and the securities of Gilead; Gilead's ability to consummate the offering in the currently anticipated timeframe or at all; the risk that Gilead's planned investments may not achieve their intended benefits; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent quarterly reports, as filed with the SEC. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514676730/en/

Ashleigh Koss, Media

public_affairs@gilead.com

Jacquie Ross, Investors

investor_relations@gilead.com

Gilead Prices $3 Billion of Senior Unsecured Notes